So-Young International Inc.
NASDAQ:SYMedical - Healthcare Information Services
-$0.09 today
- Market cap
- $239.36M
- Beta
- 1.98
- P/E (TTM)
- -5.0
- EPS (TTM)
- -$1.95
Volume 0.46M
Average 0.63M
SY Income Before Tax
Profit after all operating and non-operating items but before income tax.
So-Young International Inc.NASDAQ: SY
Income Before Tax · Q1 FY2026 · quarter ended Mar 2026
Income before tax remains negative
Q1 FY2026 income before tax was -CN¥50.65M, compared with -CN¥34.76M a year earlier. Trailing-twelve-month income before tax was -CN¥260.42M.
Context
- Income before tax amounted to 16.2% of revenue in FY2025, down 23.9 pp from a year earlier.
- Income before tax increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly income before tax holds near -CN¥50.65M or moves back toward the trailing-twelve-month quarterly average of -CN¥65.1M.
Sources:Income StatementText generated from reported figures; not investment advice.
Income Before Tax history
CNY · from the income statement
- Latest · FY2025
- (239.4M) CNY
- Year-over-year change
- +59.3%
| Period | Period end | Income Before Tax | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (239.4M) | +59.3% |
| FY2024 | 2024-12-31 | (588.09M) | -7573.5% |
| FY2023 | 2023-12-31 | 7.87M | +109.0% |
| FY2022 | 2022-12-31 | (87.07M) | -430.8% |
| FY2021 | 2021-12-31 | (16.41M) | — |
Income Before Tax vs competitors
How SY compares with its peers on the latest reported figures
- Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +56.6% is the 3rd highest of 11, against a peer median of -7.0%.
- Income before tax amounts to 15.8% of revenue for SY, versus a peer median of 90.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $86.08M USD | +148.8% | — | 870.1% | |
| LTM Mar 2026 | -$26.09M USD | +85.3% | — | 37.5% | |
| LTM Feb 2026 | -$66.3M USD | -877.2% | — | 82.3% | |
| LTM Apr 2026 | -$75.1M USD | -552.4% | — | 8.8% | |
| LTM Mar 2026 | -$79.67M USD | -23.0% | — | 98.1% | |
| LTM Mar 2026 | -$87.83M USD | +19.8% | — | 101.8% | |
| LTM Mar 2026 | -$100.45M USD | -133.2% | — | 24.4% | |
| LTM Mar 2026 | -$136.14M USD | +9.0% | — | 171.9% | |
| LTM Mar 2026 | -$221.04M USD | -23.7% | — | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$222.34M USD | +13.7% | — | — |
| LTM Mar 2026 | -CN¥260.42M CNY | +56.6% | — | 15.8% | |
| Peer median (excluding SY) | — | -7.0% | — | 90.2% | |
Competitors are the stored peer set for SY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.69B | 1.26B | 1.5B | 1.47B | 1.48B |
| Cost of Revenue | 327.89M | 393.29M | 544.34M | 567.59M | 774.04M |
| Gross Profit | 1.36B | 864.58M | 953.69M | 899.11M | 707.86M |
| Gross Margin | 80.6% | 68.7% | 63.7% | 61.3% | 47.8% |
| Research & Development | 286.57M | 235.09M | 203.52M | 165.03M | 133.31M |
| Selling, General & Admin | 1.04B | 732.3M | 811.22M | 818.57M | 833.76M |
| Operating Expenses | 1.4B | 967.39M | 1.01B | 1.52B | 967.07M |
| Depreciation & Amortization | 30.08M | 47.09M | 46.09M | 46.09M | 57.21M |
| EBITDA | 63.39M | (39.99M) | 53.96M | (38.39M) | (182.19M) |
| EBITDA Margin | 3.7% | -3.2% | 3.6% | -2.6% | -12.3% |
| Operating Income | (32.57M) | (102.81M) | (61.05M) | (624.49M) | (259.21M) |
| Operating Margin | -1.9% | -8.2% | -4.1% | -42.6% | -17.5% |
| Interest Income | 19.33M | 28.88M | 48.84M | 46.51M | 24.6M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 16.17M | 15.73M | 68.92M | 36.41M | 19.8M |
| Income Before Tax | (16.41M) | (87.07M) | 7.87M | (588.09M) | (239.4M) |
| Pre-Tax Margin | -1.0% | -6.9% | 0.5% | -40.1% | -16.2% |
| Income Tax Expense | 21.23M | (20.97M) | (18.08M) | (905K) | (774.31K) |
| Net Income | (8.37M) | (65.55M) | 21.28M | (589.53M) | (235.7M) |
| Net Margin | -0.5% | -5.2% | 1.4% | -40.2% | -15.9% |
| EPS (Basic) | (0.06) | (0.48) | 0.16 | (4.40) | (1.78) |
| EPS (Diluted) | (0.06) | (0.48) | 0.16 | (4.39) | (1.78) |
| Weighted Avg Shares | 138.04M | 138.04M | 133.19M | 134.09M | 131.59M |
| Weighted Avg Shares (Diluted) | 138.04M | 138.04M | 131.91M | 134.16M | 131.59M |
So-Young International Inc.
NASDAQ:SY
Intrinsic Alpha fair value
Locked
Current Price
$1.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.